DUBLIN – (COMMERCIAL THREAD)–The “Europe MiRNA Sequencing and Assay Market Forecast to 2027 – COVID-19 Impact and Regional Analysis by Product, Technology and End User” report was added to ResearchAndMarkets.com offer.
The European miRNA sequencing and assay market is expected to reach US $ 144.87 million by 2027, compared to US $ 62.30 million in 2019; it is expected to grow at a CAGR of 11.3% from 2020 to 2027.
Expanding the range of microRNA applications and increasing funding for genomics research. However, challenges associated with the delivery, efficacy, and specificity of miRNA-based therapies are hampering market growth.
MicroRNAs (miRNAs) are non-coding RNAs that are partially complementary to messenger RNA (mRNA). They are known to downregulate expression, making them essential regulators of important cellular functions. Involved in the process of differentiation, they act as markers in the identification of cell types. MiRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis.
Extensive research is underway to identify new miRNAs. In addition, new findings regarding the role of miRNAs in disease development have made them a key target for new therapeutic approaches. Several therapies targeting miRNAs against diseases such as cancer and hepatitis have reached the clinical phase.
For example, Santaris Pharma has developed a therapeutic molecule named Miravirsen which targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in a Phase II clinical trial. Therefore, increasing funding for genomic research to identify new molecules to diagnose and treat disease, and the consequent expansion of the range of miRNA applications is driving the growth of the miRNA sequencing and assay market in Europe.
The COVID-19 pandemic has had serious effects on European countries. The market for miRNA sequencing and assaying in the region experienced a shortage at the onset of the pandemic crisis due to supply chain disruptions and declining demands due to lockdowns imposed by many European countries. However, later on, the demand for miRNA sequencing and assay products increased dramatically due to supporting government initiatives.
Many private research organizations have expanded their research teams and projects to accelerate studies related to SARS-CoV-2. For example, QIAGEN in Germany, a pioneer in next-generation sequencing (NGS), has expanded its integrated next-generation coronavirus sequencing platforms and software solutions to accelerate COVID-19 research. Therefore, the COVID-19 pandemic has supported the growth of the miRNA sequencing and assay market in Europe.
Main topics covered:
1.1 Scope of the study
1.2 Orientation of the research report
1.3 Market segmentation
2. MiRNA Sequencing and Assay Market – Key Points to Remember
3. Research methodology
4. Sequencing and assaying miRNAs in Europe – Market landscape
4.2 PEST analysis
4.2.1 Europe – PEST analysis
4.3 Expert advice
5. MiRNA Sequencing and Assay Market – Key Market Dynamics
5.1 Main market drivers
5.1.1 Expanding the range of microRNA applications
5.1.2 Increased funding for genomics research
5.2 Market restrictions
5.2.1 Challenges related to the delivery, efficacy and specificity of miRNA-based therapies
5.3 Market opportunities
5.3.1 Growing prevalence of chronic and infectious diseases
5.4 Future trends
5.4.1 Development and launch of innovative products
5.5 Impact analysis
6. MiRNA Sequencing and Assay Market – Analysis in Europe
6.1 Europe MiRNA Sequencing and Assay Market Revenue Forecast and Analysis
7. MiRNA Sequencing and Assay Market Analysis – By Product
7.2 miRNA Sequencing and Assay Market Revenue Share, by Product (2019 & 2027)
7.3 Preparation of the library
8. MiRNA Sequencing and Assay Market Analysis – By Technology
8.2 miRNA Sequencing and Assay Market Share, by Technology, 2019 and 2027, (%)
8.3 Sequencing by synthesis
8.5 Ion semiconductor sequencing
9. MiRNA Sequencing and Assay Market Analysis – By End User
9.2 MiRNA Sequencing and Assay Market Share, by End User, 2019 and 2027, (%)
9.3 Research institute
9.5 Contract research organizations (CROs)
10. MiRNA Sequencing and Assay Market – Analysis in Europe
10.1 Europe: miRNA sequencing and assay market
10.1.2 Europe: MiRNA sequencing and assay market, by country, 2019 and 2027 (%)
11. Impact of the COVID-19 pandemic on the European miRNA sequencing and assay market
12. Industry landscape
12.2 Organic developments
12.3 Inorganic developments
13. Company profiles
Thermo Fisher Scientific
Perkin Elmer, Inc.
Takara Bio Inc.
New England Biolabs
Norgen Biotek Corp.
TriLink BioTechnologies Inc.
Oxford Nanopore Technologies
For more information on this report, visit https://www.researchandmarkets.com/r/bpg4ra